Volgens een poster-presentatie tijdens de internationale HHV6-conferentie in Parijs
komen persistente actieve
HHV-6 and HHV-7co-infecties veel vaker voor in ME/CVS
en zou een actieve HHV-7-infectie kunnen resulteren in een actieve HHV6-infectie.
Co-infection of HHV-6 and HHV-7 in patients with myalgic
encephalomyelitis/chronic fatigue syndrome.
8th International Conference on HHV-6 & 7
April 8-10, 2013 in Paris, France,
hosted by HHV-6 Foundation. Poster 12-4.
Santa Rasa, Svetlana Chapenko, Zaiga Nora-Krukle,
Angelika Krumina, Ludmila Viksna, Modra Murovska.
HHV-6 and HHV-7 infection
has been considered as a possible trigger factor in
myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
The objective of this work was to study
the association of HHV-6 and HHV-7 co-infection with ME/CFS.
165 patients (57 male and 109 female, mean age 38 years) with ME/CFS and
150 apparently healthy age and gender matched individuals
were enrolled in this study.
Nested polymerase chain reaction (nPCR) was used
to detect genomic sequences of HHV-6 and HHV-7.
Latent infection was defined as
the detection of HHV-6 or HHV-7 DNA
in the peripheral blood leukocytes (PBL)
but not in the cell free blood plasma.
Active infection was defined as
the detection of DNA in both the PBL and the plasma.
Persistent HHV-6 and/or HHV-7 infection in latent phase
was detected in
77/165 (46.7%) and 88/150 (58.7%) (p=0.0419);
whereas in active phase detection
was in 77/165 (46.7%) and 12/150 (8%)
patients with ME/CFS and apparently healthy individuals, respectively (p<0.0001).
Persistent HHV-6 and HHV-7 co-infection was found in
78/165 (47.3%) cases of ME/CFS and
23/150 (15.3%) of apparently healthy individuals (p<0.0001).
Persistent co-infection in active phase was found
in none of the apparently healthy individuals,
whereas in 78 patients with persistent co-infection,
single HHV-7 (23; 29.5%)
was observed more frequently (p<0.0001)
than single HHV-6 activation (5; 6.4%).
Simultaneous activation of
both HHV-6 and HHV-7
was detected in 17 (21.8%) patients with ME/CFS,
showing that activation of
HHV-6 occurs more frequently
in the presence of active HHV-7 (p=0.0062).
Persistent HHV-6 and HHV-7 co-infection in active phase
could be used as one of the biomarkers for ME/CFS.
According to previous in vitro studies,
infection with HHV-7 results in activation of HHV-6,
therefore in case of HHV-6 and HHV-7 co-infection,
HHV-7 infection in active phase
could be responsible for HHV-6 activation
leading to active co-infection.